Advertisement


Heinz-Josef Lenz, MD, and Marc Ychou, MD, on Treating mCRC With Initially Nonresectable Liver Metastases

2016 ASCO Annual Meeting

Advertisement

Heinz-Josef Lenz, MD, of the University of Southern California, and Marc Ychou, MD, of the Centre Régional de Lutte Contre Le Cancer, discuss study findings on FOLFIRINOX combined with targeted therapy according to RAS status for colorectal cancer patients with initially nonresectable liver metastases (Abstract 3512).



Related Videos

Pancreatic Cancer

John P. Neoptolemos, MD, PhD, on Pancreatic Ductal Adenocarcinoma: Results of the ESPAC-4 Trial

John P. Neoptolemos, MD, PhD, of the University of Liverpool, discusses findings from this international phase III study of adjuvant combination chemotherapy: gemcitabine and capecita...

Multiple Myeloma

Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma: Expert Perspectives on Treatment Advances

Sagar Lonial, MD, of Emory University School of Medicine, and Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, discuss the top presentations on multiple m...

Gynecologic Cancers

Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial

Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant...

Bladder Cancer

Arjun Vasant Balar, MD, on Urothelial Carcinoma: Analysis of the IMvigor210 Cohort 1

Arjun Vasant Balar, MD, of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses findings on atezolizumab as first-line therapy in cisplatin-ineligible locally advance...

Breast Cancer

Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes

Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completi...

Advertisement

Advertisement



Advertisement